Original articles

Value of anti-melanoma differentiation-related gene 5 antibody for assessing disease activity and prognosis in patients with dermatomyositis-associated interstitial lung disease

Expand
  • 1. Department of Clinical Laboratory, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
    2. Department of Rheumatology, South Campus, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201112, China

Received date: 2019-01-02

  Online published: 2019-04-25

Abstract

Objective: To study the expression level of anti-melanoma differentiation gene 5 antibody (anti-MDA5 antibody) in serum of idiopathic inflammatory myopathy (IIM) patients associated with interstitial lung disease (ILD), and to explore the relationship between anti-MDA5 antibody and clinical characteristics, severity and 6-month mortality of IIM-ILD patients for providing laboratory evidences to delineate new immune intervention pathway. Methods: The expression of anti-MDA5 antibody in serum of 104 patients with IIM or IIM-ILD, including polymyositis 4 cases, dermatomyositis 8 cases, amyopathic dermatomyositis, 7 cases, polymyositis-ILD 17 cases, dermatomyositis-ILD 25 cases, amyopathic dermatomyositis-ILD 43cases, and normal control group was detected by ELISA, and the relationships between anti-MDA5 antibody and lung function [FVC% and DLCO/SB (single breath, carbon monoxide diffusing capacity)], lung structure [HRCT score (high resolution CT score)] and 6-month survival were analyzed. Results: In patients with amyopathic dermatomyositis (ADM), the serum level of anti-MDA5 antibody was higher than that of normal controls, patients with dermatomyositis (DM), IIM not associated with ILD and polymyositis (PM) with ILD(P<0.005). Compared with DM-ILD patients, the serum level of anti-MDA5 antibody in patients with ADM-ILD was increased (P<0.05). There was no correlation between anti-MDA5 antibody level and lung function in patients with IIM (FVC% r=-0.04425 P=0.7579, DLCO/SB, r=-0.06839 P=0.6335), and was positively correlated with lung structural changes (r=0.3879 P=0.0002). The 6-month mortality of IIM patients with positive anti-MDA5 antibody was significantly different from that of anti-MDA5 antibody negative patients (P=0.0002). Conclusions: The anti-MDA5 antibody level detected by ELISA is closely correlated with lung function, severity of lung structural damage and mortality in patients with DM-ILD, especially ADM-ILD.

Cite this article

WANG Juan, WANG Kaiwen, ZHAO Jiangfeng . Value of anti-melanoma differentiation-related gene 5 antibody for assessing disease activity and prognosis in patients with dermatomyositis-associated interstitial lung disease[J]. Journal of Diagnostics Concepts & Practice, 2019 , 18(2) : 155 -159 . DOI: 10.16150/j.1671-2870.2019.02.007

References

[1] 中华医学会风湿病学分会. 多发性肌炎和皮肌炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(12):828-831.
[2] Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis[J]. Curr Opin Rheumatol, 2005, 17(6):701-706.
[3] Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis[J]. Eur Respir J, 2003, 22(2):245-250.
[4] Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis[J]. Rheumatology (Oxford), 2005, 44(10):1282-1286.
[5] Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study[J]. Clin Rheumatol, 2007, 26(10):1647-1654.
[6] Ghirardello A, Zampieri S, Iaccarino L, et al. Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients[J]. Reumatismo, 2005, 57(1):22-28.
[7] Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis[J]. Arthritis Care Res(Hoboken), 2013, 65(8):1316-1324.
[8] Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5):797-798.
[9] Ikezoe J, Johkoh T, Kohno N, et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis[J]. J Thorac Imaging, 1996, 11(4):250-259.
[10] Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease[J]. Arthritis Rheum, 2009, 60(7):2193-200.
[11] Mukae H, Ishimoto H, Sakamoto N, et al. Clinical diffe-rences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis[J]. Chest, 2009, 136(5):1341-1347.
[12] Sato S, Murakami A, Kuwajima A, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies[J]. PLoS One, 2016, 11(4):e0154285.
[13] Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis[J]. Ann Rheum Dis, 2018, 77(4):602-611.
Outlines

/